PURPOSE: Activated microglia play a key role in inflammatory demyelinating injury in multiple sclerosis (MS). Microglial activation can be measured in vivo using a positron emission tomography (PET) ligand (11)C-PBR28. We evaluated the test-retest variability (TRV) and lesion detectability of (11)C-PBR28 binding in MS subjects and healthy controls (HCs) with high-resolution PET. METHODS: Four clinically and radiologically stable relapsing-remitting MS subjects (age 41 ± 7 years, two men/two women) and four HCs (age 42 ± 8 years, 2 two men/two women), matched for translocator protein genotype [two high- and two medium-affinity binders according to DNA polymorphism (rs6971) in each group], were studied for TRV. Another MS subject (age 41 years, male) with clinical and radiological activity was studied for lesion detectability. Dynamic data were acquired over 120 min after injection of 634 ± 101 MBq (11)C-PBR28. For the TRV study, subjects were scanned twice, on average 1.4 weeks apart. Volume of distribution (V T) derived from multilinear analysis (MA1) modeling (t* = 30 min, using arterial input data) was the main outcome measure. RESULTS: Mean test V T values (ml cm(-3)) were 3.9 ± 1.4 in the whole brain gray matter (GM), 3.6 ± 1.2 in the whole brain white matter (WM) or normal-appearing white matter (NAWM), and 3.3 ± 0.6 in MS WM lesions; mean retest V T values were 3.7 ± 1.0 in GM, 3.3 ± 0.9 in WM/NAWM, and 3.3 ± 0.7 in MS lesions. Test-retest results showed a mean absolute TRV ranging from 7 to 9 % across GM, WM/NAWM, and MS lesions. High-affinity binders demonstrated 30 % higher V T than medium-affinity binders in GM. Focal (11)C-PBR28 uptake was detected in two enhancing lesions of the active MS patient. CONCLUSION: High-resolution (11)C-PBR28 PET can visualize focal areas where microglial activation is known to be present and has good test-retest reproducibility in the human brain. (11)C-PBR28 PET is likely to be valuable for monitoring both MS disease evolution and response to therapeutic strategies that target microglial activation.
PURPOSE: Activated microglia play a key role in inflammatory demyelinating injury in multiple sclerosis (MS). Microglial activation can be measured in vivo using a positron emission tomography (PET) ligand (11)C-PBR28. We evaluated the test-retest variability (TRV) and lesion detectability of (11)C-PBR28 binding in MS subjects and healthy controls (HCs) with high-resolution PET. METHODS: Four clinically and radiologically stable relapsing-remitting MS subjects (age 41 ± 7 years, two men/two women) and four HCs (age 42 ± 8 years, 2 two men/two women), matched for translocator protein genotype [two high- and two medium-affinity binders according to DNA polymorphism (rs6971) in each group], were studied for TRV. Another MS subject (age 41 years, male) with clinical and radiological activity was studied for lesion detectability. Dynamic data were acquired over 120 min after injection of 634 ± 101 MBq (11)C-PBR28. For the TRV study, subjects were scanned twice, on average 1.4 weeks apart. Volume of distribution (V T) derived from multilinear analysis (MA1) modeling (t* = 30 min, using arterial input data) was the main outcome measure. RESULTS: Mean test V T values (ml cm(-3)) were 3.9 ± 1.4 in the whole brain gray matter (GM), 3.6 ± 1.2 in the whole brain white matter (WM) or normal-appearing white matter (NAWM), and 3.3 ± 0.6 in MS WM lesions; mean retest V T values were 3.7 ± 1.0 in GM, 3.3 ± 0.9 in WM/NAWM, and 3.3 ± 0.7 in MS lesions. Test-retest results showed a mean absolute TRV ranging from 7 to 9 % across GM, WM/NAWM, and MS lesions. High-affinity binders demonstrated 30 % higher V T than medium-affinity binders in GM. Focal (11)C-PBR28 uptake was detected in two enhancing lesions of the active MS patient. CONCLUSION: High-resolution (11)C-PBR28 PET can visualize focal areas where microglial activation is known to be present and has good test-retest reproducibility in the human brain. (11)C-PBR28 PET is likely to be valuable for monitoring both MS disease evolution and response to therapeutic strategies that target microglial activation.
Authors: Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: Jonas Hannestad; Nicole DellaGioia; Jean-Dominique Gallezot; Keunpoong Lim; Nabeel Nabulsi; Irina Esterlis; Brian Pittman; Jae-Yun Lee; Kevin C O'Connor; Daniel Pelletier; Richard E Carson Journal: Brain Behav Immun Date: 2013-07-09 Impact factor: 7.217
Authors: E M Mowry; A Beheshtian; E Waubant; D S Goodin; B A Cree; P Qualley; R Lincoln; M F George; R Gomez; S L Hauser; D T Okuda; D Pelletier Journal: Neurology Date: 2009-05-19 Impact factor: 9.910
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Aurelija Jučaite; Zsolt Cselényi; Annie Arvidsson; Gabrielle Ahlberg; Per Julin; Katarina Varnäs; Per Stenkrona; Jan Andersson; Christer Halldin; Lars Farde Journal: EJNMMI Res Date: 2012-04-23 Impact factor: 3.138
Authors: Christine M Sandiego; Jean-Dominique Gallezot; Brian Pittman; Nabeel Nabulsi; Keunpoong Lim; Shu-Fei Lin; David Matuskey; Jae-Yun Lee; Kevin C O'Connor; Yiyun Huang; Richard E Carson; Jonas Hannestad; Kelly P Cosgrove Journal: Proc Natl Acad Sci U S A Date: 2015-09-18 Impact factor: 11.205
Authors: Christin Schifani; Sina Hafizi; Huai-Hsuan Tseng; Cory Gerritsen; Miran Kenk; Alan A Wilson; Sylvain Houle; Pablo M Rusjan; Romina Mizrahi Journal: Schizophr Res Date: 2018-11-06 Impact factor: 4.939
Authors: Ansel T Hillmer; David Matuskey; Yiyun Huang; Nabeel Nabulsi; Jim Ropchan; Richard E Carson; Stephanie S O'Malley; Kelly P Cosgrove Journal: J Nucl Med Date: 2020-01-31 Impact factor: 10.057
Authors: Valeria T Barletta; Elena Herranz; Costantina A Treaba; Russell Ouellette; Ambica Mehndiratta; Marco L Loggia; Eric C Klawiter; Carolina Ionete; Sloane A Jacob; Caterina Mainero Journal: Mult Scler Date: 2019-04-11 Impact factor: 6.312
Authors: Jeffrey H Meyer; Simon Cervenka; Min-Jeong Kim; William C Kreisl; Ioline D Henter; Robert B Innis Journal: Lancet Psychiatry Date: 2020-10-21 Impact factor: 27.083
Authors: Sujata Sridharan; Joel Raffel; Ashwini Nandoskar; Chris Record; David J Brooks; David Owen; David Sharp; Paolo A Muraro; Roger Gunn; Richard Nicholas Journal: Mol Imaging Biol Date: 2019-10 Impact factor: 3.488
Authors: Elena Herranz; Costanza Giannì; Céline Louapre; Constantina A Treaba; Sindhuja T Govindarajan; Russell Ouellette; Marco L Loggia; Jacob A Sloane; Nancy Madigan; David Izquierdo-Garcia; Noreen Ward; Gabriel Mangeat; Tobias Granberg; Eric C Klawiter; Ciprian Catana; Jacob M Hooker; Norman Taylor; Carolina Ionete; Revere P Kinkel; Caterina Mainero Journal: Ann Neurol Date: 2016-10-25 Impact factor: 10.422